


POPular TAVI (antiplatelet therapy)

#ESCCongress



AMERICAN COLLEGE of CARDIOLOGY

Trial Description: Patients who underwent TAVR were randomized to aspirin alone versus aspirin and clopidogrel for 3 months.



RESULTS

- Co-primary endpoint, all bleeding (minor, major, and life-threatening or disabling bleeding) at 12 months, occurred in 15.1% of the aspirin alone group compared with 26.6% of the aspirin plus clopidogrel group (p = 0.001)
- Co-primary outcome, nonprocedure-related bleeding at 12 months, occurred in 15.1% of the aspirin alone group compared with 24.9% of the aspirin plus clopidogrel group (p = 0.005)

CONCLUSIONS

- Among patients who underwent TAVR and did not have an indication for anticoagulation, aspirin alone was associated with a reduction in all bleeding and nonprocedure-related bleeding compared with aspirin plus clopidogrel
- Benefit was largely due to a significant reduction in major bleeding events

Brouwer J, et al. *N Engl J Med* 2020;383:144-57